ストックスクリーナーアプリを入手
68.11
0.58%
0.39
アフターアワーズ：
68.11
前日終値:
$67.72
開ける：
$67.08
24時間の取引高:
690.45K
Relative Volume:
0.90
時価総額：
$3.42B
収益：
$379.25M
当期純損益:
$-77.34M
株価収益率:
-42.25
EPS:
-1.6122
ネットキャッシュフロー:
$-27.87M
1週間 パフォーマンス:
-6.25%
1か月 パフォーマンス:
-7.63%
6か月 パフォーマンス:
+65.24%
1年 パフォーマンス:
+65.80%
1日の値動き範囲:
$66.79
$69.26
1週間の範囲:
$66.79
$74.00
52週間の値動き範囲:
$36.88
$78.54
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
名前
Mirum Pharmaceuticals Inc
セクター
電話
650-667-4085
住所
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
68.11 | 3.48B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-24 | 開始されました | TD Cowen | Buy |
| 2025-08-11 | 再開されました | Stifel | Buy |
| 2025-05-19 | 再開されました | H.C. Wainwright | Buy |
| 2024-04-17 | 開始されました | Stifel | Buy |
| 2023-12-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-13 | 開始されました | Morgan Stanley | Overweight |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 再開されました | Evercore ISI | Outperform |
| 2023-09-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2021-09-20 | 開始されました | JP Morgan | Overweight |
| 2020-08-07 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-25 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-12 | 開始されました | Citigroup | Buy |
| 2019-08-12 | 開始されました | Evercore ISI | Outperform |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | ROTH Capital | Buy |
| 2019-08-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Responsive Playbooks and the MIRM Inflection - news.stocktradersdaily.com
Mirum to present new data on liver disease therapies at AASLD meeting - Investing.com
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting - Investing News Network
Mirum to present new data on liver disease therapies at AASLD meeting By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting® - Markets Financial Content
Is Mirum Pharmaceuticals Inc. stock overvalued by current metrics2025 Short Interest & Verified Technical Signals - newser.com
Mirum Pharmaceuticals engages at NASPGHAN 2025 Annual Meeting - Traders Union
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2025 Earnings Call Transcript - Insider Monkey
Published on: 2025-11-06 04:51:32 - newser.com
Why Mirum Pharmaceuticals Inc. stock is rated strong buy2025 Technical Overview & Consistent Profit Focused Trading Strategies - fcp.pa.gov.br
Is Mirum Pharmaceuticals Inc. (08D) stock worth buying before Fed action2025 Momentum Check & Weekly Breakout Watchlists - newser.com
Will Mirum Pharmaceuticals Inc. stock outperform tech sector in 2025Market Sentiment Summary & Risk Controlled Stock Alerts - fcp.pa.gov.br
Is Mirum Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - newser.com
Mirum Pharmaceuticals (MIRM): Discounted Valuation Reinforces Bullish Narrative on Profit Breakthrough Potential - Yahoo Finance
Citizens Maintains Mirum Pharmaceuticals (MIRM) Market Outperform Recommendation - Nasdaq
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened - sharewise.com
Will Mirum Pharmaceuticals Inc. stock gain from government policies2025 Institutional Moves & Community Consensus Stock Picks - fcp.pa.gov.br
Mirum Pharmaceuticals (MIRM) Projected to Post Earnings on Tuesday - MarketBeat
Will breakout in Mirum Pharmaceuticals Inc. lead to full recovery2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
What Analysts Are Saying About Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals stock price target raised to $95 by Citizens - Investing.com Canada
Will Mirum Pharmaceuticals Inc. (08D) stock keep high P E multiplesJuly 2025 PostEarnings & AI Driven Stock Price Forecasts - newser.com
Why Mirum Pharmaceuticals Inc. stock remains undervaluedTrend Reversal & Reliable Entry Point Trade Alerts - newser.com
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Mirum Pharmaceuticals Reports Strong Q3 2025 Growth - TipRanks
Decoding Mirum Pharmaceuticals Inc (MIRM): A Strategic SWOT Insi - GuruFocus
Mirum Pharmaceuticals earnings beat by $0.20, revenue topped estimates - Investing.com Canada
Earnings Call Summary | Mirum Pharmaceuticals(MIRM.US) Q3 2025 Earnings Conference - 富途牛牛
How to build a custom watchlist for Mirum Pharmaceuticals Inc.Earnings Trend Report & Technical Buy Zone Confirmation - newser.com
Earnings call transcript: Mirum Pharmaceuticals reports Q3 2025 earnings beat By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Investing News Network
(MIRM) Mirum Pharmaceuticals Expects Full Year 2025 Revenue Range $500 Million$510 Million, vs. FactSet Est of $506.4 Million - MarketScreener
Earnings call transcript: Mirum Pharmaceuticals reports Q3 2025 earnings beat - Investing.com
Mirum Pharmaceuticals Lifts Guidance After LIVMARLI Sales Surge - Finimize
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings: EPS of $0.06 - GuruFocus
Earnings Flash (MIRM) Mirum Pharmaceuticals, Inc. Reports Q3 Revenue $133.0M, vs. FactSet Est of $130.5M - MarketScreener
Mirum Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2025 - MarketScreener
[10-Q] Mirum Pharmaceuticals, Inc. Quarterly Earnings Report | MIRM SEC FilingForm 10-Q - Stock Titan
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth - MarketScreener
[8-K] Mirum Pharmaceuticals, Inc. Reports Material Event | MIRM SEC FilingForm 8-K - Stock Titan
Mirum Pharmaceuticals Q3 2025 Earnings Preview - MSN
How currency fluctuations impact Mirum Pharmaceuticals Inc. stock2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
Will Mirum Pharmaceuticals Inc. see short term momentumMarket Risk Analysis & Safe Entry Zone Tips - newser.com
Mirum Pharmaceuticals to Participate in Upcoming November 2025 Investor Conferences - BioSpace
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Why analysts remain bullish on Mirum Pharmaceuticals Inc. stockAnalyst Upgrade & Smart Allocation Stock Tips - newser.com
Is it time to cut losses on Mirum Pharmaceuticals Inc.Weekly Volume Report & High Yield Equity Trading Tips - newser.com
Mirum Pharmaceuticals, Inc. (MIRM) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Mirum Pharmaceuticals Inc (MIRM) 財務データ
収益
当期純利益
現金流量
EPS
Mirum Pharmaceuticals Inc (MIRM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Brege Laura | Director |
Sep 11 '25 |
Sale |
74.40 |
17,000 |
1,264,868 |
15,703 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER |
Sep 12 '25 |
Sale |
76.01 |
9,578 |
728,024 |
39,945 |
5.44%
0.70%
大文字化:
|
ボリューム (24 時間):